Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models

Nanomedicine

Volumn 11, Issue 18, 2016, Pages 2431-2441

  Hadla, Mohamad ^a,b   Palazzolo, Stefano ^a,c   Corona, Giuseppe ^a   Caligiuri, Isabella ^a   Canzonieri, Vincenzo ^a   Toffoli, Giuseppe ^a   Rizzolio, Flavio ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

breast and ovarian cancers; doxorubicin; drug delivery; exosomes; therapeutic index

Indexed keywords

DOXORUBICIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CAPILLARY ENDOTHELIAL CELL; CARDIOTOXICITY; CELL TRACKING; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EXOSOME; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NANOPARTICLE TRACKING ANALYSIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; THERAPEUTIC INDEX; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BREAST NEOPLASMS; CARDIAC MUSCLE; CHEMISTRY; DRUG SCREENING; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; EXOSOMES; FEMALE; HUMANS; MICE; MYOCARDIUM; NANOPARTICLES; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84984714282     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0154     Document Type: Article

References (46)

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56(2), 185-229 (2004).
2. Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discov. 11(10), 751-761 (2012).
3. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363(4), 301-304 (2010).
4. Kunjachan S, Ehling J, Storm G, Kiessling F, Lammers T. Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects. Chem. Rev. 115 (19), 10907-10937 (2015).
5. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
6. Rizzolio F, Esposito L, Muresu D et al. RB gene family: genome-wide ChIP approaches could open undiscovered roads. J. Cell. Biochem. 109(5), 839-843 (2009).
7. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33(9), 941-951 (2015).
8. Wolfram J, Shen H, Ferrari M. Multistage vector (MSV) therapeutics. J. Control. Release 219, 406-415 (2015).
9. Ojha T, Rizzo L, Storm G, Kiessling F, Lammers T. Image-guided drug delivery: preclinical applications and clinical translation. Expert Opin. Drug Deliv. 12(8), 1203-1207 (2015).
10. Kumar V, Palazzolo S, Bayda S, Corona G, Toffoli G, Rizzolio F. DNA nanotechnology for cancer therapy. Theranostics 6(5), 710-725 (2016).
11. Gobbo OL, Sjaastad K, Radomski MW, Volkov Y, Prina-Mello A. Magnetic nanoparticles in cancer theranostics. Theranostics 5(11), 1249-1263 (2015).
12. ®-The frst FDA-approved nano-drug: lessons learned. J. Control. Release 160(2), 117-134 (2012).
13. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42(5), 419-436 (2003).
14. Guo P, Yang J, Jia D, Moses MA, Auguste DT. ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer. Theranostics 6(1), 1-13 (2016).
15. Raposo G, Stoorvogel W Extracellular vesicles: exosomes, microve sicles, and friends. J. Cell Biol. 200(4), 373-383 (2013).
16. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J. Proteomics 73 (10), 1907-1920 (2010).
17. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007).
18. Melo SA, Luecke LB, Kahlert C et al. Glypican-1 identifes cancer exosomes and detects early pancreatic cancer. Nature 523(7559), 177-182 (2015).
19. Yoo J-W, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov. 10(7), 521-535 (2011).
20. Haque ME, McIntosh TJ, Lentz BR. Influence of lipid composition on physical properties and peg-mediated fusion of curved and uncurved model membrane vesicles: 'nature's own' fusogenic lipid bilayer. Biochemistry 40 (14), 4340-4348 (2001).
21. Kooijmans SAA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomedicine 7, 1525-1541 (2012).
22. Marcus ME, Leonard JN. FedExosomes: engineering therapeutic biological nanoparticles that truly deliver. Pharmaceuticals (Basel) 6(5), 659-680 (2013).
23. Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J. Control. Release 161(2), 600-608 (2012).
24. Katakowski M, Buller B, Zheng X et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 335(1), 201-204 (2013).
25. Khatua AK, Taylor HE, Hildreth JEK, Popik W Exosomes packaging APOBEC3G confer human immunodefciency virus resistance to recipient cells. J. Virol. 83(2), 512-521 (2009).
26. Takahashi K, Yan IK, Kogure T, Haga H, Patel T. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio. 4, 458-467 (2014).
27. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341-345 (2011).
28. Toffoli G, Hadla M, Corona G et al. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. Nanomedicine (Lond). doi:10.2217/nnm.15.118 (2015) (Epub ahead of print).
29. Kim MS, Haney MJ, Zhao Y et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12(3), 655-664 (2016).
30. Saari H, Lázaro-Ibáñez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle-and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells. J. Control. Release 220(Pt B), 727-737 (2015).
31. McCloskey CW, Goldberg RL, Carter LE et al. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Front. Oncol. 4, 53 (2014).
32. Maioli M, Santaniello S, Montella A et al. Hyaluronan esters drive Smad gene expression and signaling enhancing cardiogenesis in mouse embryonic and human mesenchymal stem cells. PLoS ONE 5(11), e 15151 (2010).
33. Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle 11(20), 3828-3836 (2012).
34. Roberti A, Rizzolio F, Lucchetti C, de Leval L, Giordano A. Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines. Cell Cycle 10(1), 127-134 (2011).
35. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomedicine 2(4), 567-583 (2007).
36. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
37. Vaughan S, Coward JI, Bast RC et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11(10), 719-725 (2011).
38. Koboldt DC, Fulton RS, McLellan MD et al. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61-70 (2012).
39. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 115(2), 155-162 (2010).
40. Sharma A. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154(2), 123-140 (1997).
41. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71(11), 3792-3801 (2011).
42. Peinado H, AleCkoviC M, Lavotshkin S et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18(6), 883-891 (2012).
43. Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv. Drug Deliv. Rev. 65(3), 383-390 (2013).
44. Rana S, Malinowska K, Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 15(3), 281-295 (2013).
45. Jang SC, Kim OY, Yoon CM et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7(9), 7698-7710 (2013).
46. Tian Y, Li S, Song J et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35(7), 2383-2390 (2014).